Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

doi:10.4251/wjgo.v8.i2.173

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10420)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

698

WORD

402

HTML

4308

Figures (1-1)

556

Tables (1-3)

220

Sum=6184

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

417

Download

1054

Sum=1471

Publishing Process of This Article

Item

Count

Browse

1161

Download

1604

Sum=2765

Feb 15, 2016 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Feb 15, 2016; 8(2): 173-185
Published online Feb 15, 2016. doi: 10.4251/wjgo.v8.i2.173

Table 2 Second line trials with molecular targeted therapies in advanced hepatocellular cancer

Trial	Drugs	Design	n	Median survival	HR	P value
BRISK-PS	Brivanib vs placebo	Superiority	263	9.4	0.89	0.33
BRISK-PS	Brivanib vs placebo	Superiority	132	8.2	0.89	0.33
EVOLVE-1	Everolimus vs placebo	Superiority	362	7.6	1.05	0.68
EVOLVE-1	Everolimus vs placebo	Superiority	184	7.3	1.05	0.68
REACH	Ramucirumab vs placebo	Superiority	277	9.2	0.87	0.14
REACH	Ramucirumab vs placebo	Superiority	276	7.6	0.87	0.14

Citation: Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016; 8(2): 173-185
URL: https://www.wjgnet.com/1948-5204/full/v8/i2/173.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i2.173